According to Psychiatric News (1/14), the FDA “has issued a Drug Safety Communication [PDF] about dental problems associated with the use of buprenorphine products that dissolve in the mouth (transmucosal) and is requiring that a new warning about the risk of dental problems be added to the prescribing information and patient medication guides for these products.” Among these dental problems are “tooth decay, cavities, dental abscesses/infection, tooth erosion, or tooth loss.”
Related Links:
— “FDA Issues Warning About Dental Risk With Transmucosal Buprenorphine, Psychiatric News, January 14, 2022